Clinical trials
High Risk Prostate Cancer clinical trials
Below are recruiting high risk prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 341 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06733350RecruitingPhase 4
Testosterone therapy for low testosterone in men with low-risk prostate cancer
This study tests whether testosterone replacement therapy can safely improve low testosterone levels in men with low-risk prostate cancer who are not getting immediate treatment. It aims to help men feel better without worsening their cancer.
Buffalo, New YorkAges 18 years+ - NCT06687421Recruiting
Precision medicine for high-risk prostate cancer
This study aims to use precision medicine (tailored treatment based on your specific cancer) for men at high risk of prostate cancer. It may help doctors choose the best treatment for you.
UmeåAges 18 years+ - NCT06220435Recruiting
Radiation therapy for very high-risk localized prostate cancer
This trial tests radiation therapy for men with very high-risk prostate cancer that hasn't spread. It aims to see if targeting the tumor with radiation can help control the cancer in this highest risk group.
LundAges 18 years+ - NCT06678126RecruitingPhase 2
Adaptive vs standard radiation for prostate cancer
This trial compares two ways of giving radiation to the prostate and pelvic lymph nodes. It also tests two different instructions for how full your bladder should be during treatment. The goal is to see which approach works better and is easier for patients.
Vancouver, British ColumbiaAges 18 years+ - NCT06625970RecruitingPhase 3
Darolutamide and high-dose radiation for high-risk prostate cancer
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
BrestAges 18–80 - NCT06631521RecruitingPhase 1
Hormone pills before prostate cancer surgery
This trial tests two oral hormone drugs (darolutamide and relugolix) given before prostate removal surgery for men with high-risk prostate cancer. The goal is to see if this combination shrinks the tumor and improves treatment outcomes.
Orlando, FloridaAges 18 years+ - NCT06613100RecruitingPhase 1
Xaluritamig before prostate surgery for high-risk prostate cancer
This study tests an experimental drug called xaluritamig given before surgery for men with localized prostate cancer that is intermediate or high risk. The goal is to see if it can help shrink the cancer before the prostate is removed.
San Francisco, CaliforniaAges 18 years+ - NCT06616155RecruitingPhase 1/Phase 2
Ruxolitinib and Enzalutamide for Resistant Prostate Cancer
This trial tests two drugs—ruxolitinib and enzalutamide—together to see if they can help men whose prostate cancer has spread and stopped responding to abiraterone. It is for those whose cancer grew quickly on abiraterone.
Chicago, IllinoisAges 18 years+ - NCT06567743RecruitingPhase 2
Study of a new virus therapy for high-risk bladder cancer
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Gilbert, ArizonaAges 18 years+ - NCT06331013Recruiting
CyberKnife Radiation for Prostate Cancer
This trial tests a high-precision radiation treatment (CyberKnife SBRT) for prostate cancer that is still within the prostate. It aims to see if a very short course of radiation works well with fewer side effects.
MilanAges 18–80 - NCT06499870RecruitingPhase 2
Study of two drugs with radiation for high-risk prostate cancer
This trial tests whether combining two hormone therapy drugs, relugolix and enzalutamide, with radiation therapy can help treat very high-risk prostate cancer. The goal is to see if this combination is safe and effective for men whose cancer has a high chance of coming back.
Chicago, IllinoisAges 18 years+ - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06429813Recruiting
Remote exercise program for men with metastatic prostate cancer
This trial tests whether a remotely supervised exercise program (walking and stationary cycling) can help men with metastatic prostate cancer who are starting hormone therapy. Participation involves following an exercise plan at home and may help manage side effects.
Charlottesville, VirginiaAges 18 years+ - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06402357RecruitingPhase 2
Focused Ultrasound for Recurrent Prostate Cancer After Radiation
This trial tests if a focused ultrasound treatment can safely and effectively treat prostate cancer that has come back after radiation therapy. The ultrasound uses sound waves to heat and destroy cancer cells in a specific area of the prostate while sparing healthy tissue.
Gainesville, FloridaAges 18 years+ - NCT06389786Recruiting
Using a new PET scan to find cancer spread before prostate surgery
This trial tests a special PET/MRI scan that may help doctors see if prostate cancer has spread to nearby lymph nodes before surgery. It could help guide treatment decisions for men with high-risk prostate cancer.
Jacksonville, FloridaAges 30–85 - NCT06391034RecruitingPhase 2
MRI scan with pyruvate for prostate cancer
This trial uses a special MRI scan (with hyperpolarized pyruvate, a naturally occurring substance) to look at prostate cancer in more detail. It aims to help doctors understand how the cancer is responding to treatment or how it might behave.
San Francisco, CaliforniaAges 18 years+ - NCT06334120Recruiting
Darolutamide safety study for men with prostate cancer in Korea
This study tracks the safety of the drug darolutamide in Korean men with a type of prostate cancer that has not spread (non-metastatic) or has spread (metastatic) and is still responding to hormone therapy. It aims to see how well patients tolerate the drug in real-world settings.
Multiple LocationsAges 19 years+ - NCT06330805RecruitingPhase 2
Comparing heart effects of two hormone therapies for prostate cancer
This trial compares two hormone therapies, relugolix and leuprolide, to see which one is better for your heart health in men with prostate cancer. It's for men with a specific type of prostate cancer that is not yet advanced.
Columbus, OhioAges 18 years+ - NCT06325046Recruiting
Adaptive radiation therapy for localized prostate cancer
This trial tests a type of radiation that adapts to your body's changes during treatment. It is for men with low- to intermediate-risk prostate cancer that hasn't spread.
Albert Lea, MinnesotaAges 18 years+ - NCT06282588RecruitingPhase 2/Phase 3
Advanced imaging-guided treatment for high-risk prostate cancer
This trial uses a special PET scan (PSMA PET/CT) and a genetic test (Decipher) to decide the best treatment for high-risk prostate cancer that hasn't spread outside the pelvis. You'll receive standard radiation and hormone therapy, possibly with an extra drug (darolutamide).
Wilrijk, AntwerpAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT06200974Recruiting
Genetic study of HDR brachytherapy for low-risk prostate cancer
This study looks at a type of radiation therapy called HDR brachytherapy for men with low-risk or slightly higher risk prostate cancer. It aims to understand how your genes affect treatment outcomes.
Kelowna, British ColumbiaAges 18 years+ - NCT06130995RecruitingPhase 1
Relugolix and enzalutamide for high-risk prostate cancer
This trial tests a combination of two oral drugs, relugolix and enzalutamide, in men with high-risk prostate cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help control the cancer before or alongside local therapies like surgery or radiation.
Oklahoma City, OklahomaAges 18 years+
Hear when a new High Risk Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk prostate cancer?
- Yes. Clin2 currently lists 341 recruiting high risk prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.